Patients with MMR deficient relapse or advanced / metastatic endometrial cancer
Conditions
Brief summary
Progression Free Survival (PFS) assessed per BICR (Blinded Independent Central Review)
Detailed description
Overall survival (OS), Progression Free Survival 2 (PFS2), Quality of Life (QoL), Best objective Response Rate (ORR), Disease control rate (DCR), Duration of Response Rate (DoR), PFS, DoR as per investigator assessment, Safety and tolerability, Time to first and second Subsequent Treatment, Efficacy of second systemic therapies, To describe the pharmacokinetics of dostarlimab, To determine the immunogenicity of dostarlimab
Interventions
DRUGCARBOPLATIN
DRUGPACLITAXEL
DRUGDOSTARLIMAB
Sponsors
Arcagy Gineco
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS) assessed per BICR (Blinded Independent Central Review) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS), Progression Free Survival 2 (PFS2), Quality of Life (QoL), Best objective Response Rate (ORR), Disease control rate (DCR), Duration of Response Rate (DoR), PFS, DoR as per investigator assessment, Safety and tolerability, Time to first and second Subsequent Treatment, Efficacy of second systemic therapies, To describe the pharmacokinetics of dostarlimab, To determine the immunogenicity of dostarlimab | — |
Countries
France, Italy, Romania, Spain
Outcome results
None listed